C4 Therapeutics, Inc.
CCCC Real Time Price USDRecent trades of CCCC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CCCC's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
CCCC Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: N/o-linked degrons and degronimers for protein degradation Dec. 31, 2024
-
Patent Title: Compounds for targeted degradation of brd9 Dec. 03, 2024
-
Patent Title: Compounds for targeted degradation of brd9 Jul. 30, 2024
-
Patent Title: Spirocyclic degronimers for target protein degradation Jul. 30, 2024
-
Patent Title: Substituted piperidine degronimers for target protein degradation Jul. 30, 2024
-
Patent Title: C May. 28, 2024
-
Patent Title: Glutarimides for medical treatment Oct. 31, 2023
-
Patent Title: Dihydrobenzimidazolones for medical treatment Oct. 17, 2023
-
Patent Title: Cereblon binders for the degradation of ikaros Sep. 12, 2023
-
Patent Title: Compounds for targeted degradation of brd9 Jul. 04, 2023
-
Patent Title: Isoindolinone and indazole compounds for the degradation of egfr Jun. 13, 2023
-
Patent Title: Spirocyclic compounds Apr. 11, 2023
-
Patent Title: Spirocyclic compounds Feb. 21, 2023
-
Patent Title: Degraders and degrons for targeted protein degradation Dec. 13, 2022
-
Patent Title: N/o-linked degrons and degronimers for protein degradation Oct. 04, 2022
-
Patent Title: Tricyclic degraders of ikaros and aiolos Aug. 09, 2022
-
Patent Title: Dihydroquinolinones for medical treatment Aug. 02, 2022
-
Patent Title: Dihydrobenzimidazolones for medical treatment Feb. 22, 2022
-
Patent Title: Spirocyclic degronimers for target protein degradation Nov. 30, 2021
-
Patent Title: Heterocyclic degronimers for target protein degradation Feb. 02, 2021
-
Patent Title: C3-carbon linked glutarimide degronimers for target protein degradation Dec. 01, 2020
-
Patent Title: Spirocyclic degronimers for target protein degradation May. 26, 2020
-
Patent Title: Heterocyclic degronimers for target protein degradation May. 12, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CCCC
Number of mentions of CCCC in WallStreetBets Daily Discussion
Recent picks made for CCCC stock on CNBC
ETFs with the largest estimated holdings in CCCC
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CCCC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.